menu
    • menu
    [{"orgOrder":0,"company":"Incepta Pharmaceuticals","sponsor":"Incepta Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase IV","graph3":"Incepta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incepta Pharmaceuticals \/ Incepta Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Incepta Pharmaceuticals \/ Incepta Pharmaceuticals"},{"orgOrder":0,"company":"Incepta Pharmaceuticals","sponsor":"Institute for Developing Science and Health Initiatives, Bangladesh","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BANGLADESH","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Erythropoietin Alfa","moa":"EPO receptor","graph1":"Undisclosed","graph2":"Phase III","graph3":"Incepta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Incepta Pharmaceuticals \/ Institute for Developing Science and Health Initiatives, Bangladesh","highestDevelopmentStatusID":"10","companyTruncated":"Incepta Pharmaceuticals \/ Institute for Developing Science and Health Initiatives, Bangladesh"}]

    Find Clinical Drug Pipeline Developments & Deals by Incepta Pharmaceuticals

    Menu

    Incepta Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Incepta Pharmaceuticals

                            Bangladesh arrow
                            Vitafoods
                            Not Confirmed

                            Incepta Pharmaceuticals

                            Bangladesh arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Erythropoietin Alfa

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase III

                            Sponsor : Institute for Developing Science and Health Initiatives, Bangladesh

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PK, PD, Safety, & Immunogenicity Study of Erythropoietin with Eprex in Healthy Adults

                            Details : Erythropoietin Alfa is a Protein drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of unspecified medical condition.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            June 17, 2025

                            Lead Product(s) : Erythropoietin Alfa

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase III

                            Sponsor : Institute for Developing Science and Health Initiatives, Bangladesh

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Incepta Pharmaceuticals

                            Bangladesh arrow
                            Vitafoods
                            Not Confirmed

                            Incepta Pharmaceuticals

                            Bangladesh arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tofacitinib Citrate

                            Therapeutic Area : Immunology

                            Study Phase : Phase IV

                            Recipient : Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tofacitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Dose Escalation Study

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 13, 2024

                            Lead Product(s) : Tofacitinib Citrate

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase IV

                            Recipient : Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth